CAS 358970-97-5
:Drinabant
Description:
Drinabant is a synthetic compound that acts as a selective antagonist of the cannabinoid receptor type 1 (CB1). It is primarily studied for its potential therapeutic applications in treating obesity and related metabolic disorders by modulating appetite and energy balance. Drinabant's chemical structure features a unique arrangement of functional groups that contribute to its binding affinity and selectivity for the CB1 receptor. The compound is typically administered in a pharmaceutical context, and its efficacy and safety profile have been evaluated in various clinical trials. As a CB1 antagonist, Drinabant may help counteract the effects of endocannabinoids, which are involved in appetite regulation and fat storage. However, like many pharmacological agents, it may also present side effects, which necessitate careful consideration in its therapeutic use. Overall, Drinabant represents a significant area of research in the field of pharmacology, particularly concerning the endocannabinoid system and its implications for metabolic health.
Formula:C23H20Cl2F2N2O2S
InChI:InChI=1S/C23H20Cl2F2N2O2S/c1-32(30,31)29(21-11-19(26)10-20(27)12-21)22-13-28(14-22)23(15-2-6-17(24)7-3-15)16-4-8-18(25)9-5-16/h2-12,22-23H,13-14H2,1H3
InChI key:InChIKey=IQQBRKLVEALROM-UHFFFAOYSA-N
SMILES:C(N1CC(N(S(C)(=O)=O)C2=CC(F)=CC(F)=C2)C1)(C3=CC=C(Cl)C=C3)C4=CC=C(Cl)C=C4
Synonyms:- Ave 1625
- Methanesulfonamide, N-[1-[bis(4-chlorophenyl)methyl]-3-azetidinyl]-N-(3,5-difluorophenyl)-
- N-[1-[Bis(4-chlorophenyl)methyl]-3-azetidinyl]-N-(3,5-difluorophenyl)methanesulfonamide
- N-[1-[Bis(4-chlorophenyl)methyl]azetidin-3-yl]-N-(3,5-difluorophenyl)methanesulfonamide
- Drinabant
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
